Acme United (ACU) Stock Trades Near Analyst Consensus Targets With Low-Beta Profile

• Acme United Corporation (ACU) is currently trading near its analyst average price target of $58.00, with the stock price hovering around $61.84 .
• The stock exhibits a low beta of 0.25, indicating lower volatility relative to the broader market .
• The company maintains a healthy balance sheet with a debt-to-equity ratio of 0.32x and an interest coverage ratio of 9.05x .
• Institutional investors, led by BlackRock, significantly increased their positions in Acme United during the second quarter .

Acme United Corporation operates as a diversified manufacturer of cutting, measuring, and safety products for consumer and industrial markets. The company supplies essential safety, first-aid, and cutting instruments for institutional and consumer use. Key brands include First Aid Only, PhysiciansCare, Pac-Kit, and Westcott . The business model relies on stable demand for these critical supplies, which aligns with the stock's low-volatility profile. A market capitalization of approximately $237 million characterizes the firm's current standing . The company also maintains a dividend with a yield of 1.03% .

The most recent financial reporting period demonstrated significant outperformance against market expectations. Acme United reported second-quarter 2026 earnings per share (EPS) of $1.22 . This figure substantially exceeded analyst estimates of $0.42, representing a beat of 190.48% . Revenue also surpassed forecasts, reaching $62.7 million compared to the $58.1 million estimate . This performance marks a notable acceleration from the previous year's EPS of $1.16 .

The growth was primarily fueled by the recent acquisition of MyMedic. Total sales rose 16% year-over-year . When excluding the contribution from MyMedic, organic growth stood at a solid 8% . A key driver of profitability was the expansion of gross margins to 42.6%, up from 41.0% in the prior year period . The company generates trailing twelve-month revenue of $211.6 million and EBITDA of $22.22 million .

Why Is Institutional Interest Increasing?

Institutional investors have shown renewed confidence in Acme United's fundamentals. BlackRock Inc. purchased a new stake in the company during the second quarter . This acquisition involved 179,760 shares valued at approximately $8.58 million . The purchase increased BlackRock's ownership to about 4.72% of the company .

Other major institutions also added to their positions or initiated new ones during the period. Bank of America Corp DE significantly increased its holdings by 3,048.9% . JPMorgan Chase & Co., Mirae Asset Global ETFs Holdings Ltd., and Raymond James Financial Inc. all acquired new positions . Consequently, institutional investors and hedge funds now own 62.10% of Acme United's stock .

Conversely, corporate insiders have been selling shares recently. Director Rex Lynn Davidson sold 3,684 shares on August 10th . COO Brian S. Olschan sold 7,308 shares on August 18th . In total, insiders sold 25,722 shares worth $1.5 million over the last 90 days . Despite these sales, insiders still retain a 29.50% ownership stake .

What Are The Key Risks And Limitations?

Analyst coverage for Acme United remains limited. Freedom Capital Markets maintains a Buy rating with a price target of $53.00 . This target represents a downside of approximately 14.29% from recent trading levels around $61.84 . The target was established on March 23, 2026 . No other recent analyst actions or significant revisions to price targets are currently reflected in the consensus data . This limited coverage suggests that Acme United may be overlooked by broader institutional analyst teams .

Several operational risks warrant attention. SG&A expenses remain elevated at 32% of sales, which may pressure net income . Headwinds include potential tariff and freight cost fluctuations . Currency volatility poses another risk to the company's financial performance . Geographic performance is uneven, with the Canadian market lagging behind other regions .

Looking ahead, management anticipates continued margin recovery. This is expected to occur as the company transitions inventory . The firm plans to replace higher-tariff stock with lower-cost alternatives through the end of the year . Additionally, the integration of MyMedic is progressing . Strategic efforts are shifting from direct-to-consumer sales toward expansion into mass retail channels . The company expects strong profitability in Q4 driven by seasonal demand .

Upcoming earnings are scheduled for October 20, 2026. Estimates point to an EPS of $0.67 for the upcoming quarter . The stock recently reacted positively to earnings results, surging 17.52% on the back of these results . The company maintains a strong liquidity position with a current ratio of 4.41 and a quick ratio of 1.91 . Recent news includes the retail availability of BC3 Technologies' SEAL Hemostatic Wound Spray at Army & Air Force Exchange Service locations . This highlights the company's defense and safety product integration.